Sodium warnings "across-the-board" for orally-ingested OTCs unnecessary -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
"ACROSS-THE-BOARD" SODIUM WARNING FOR ORAL OTCs QUESTIONED BY NDMA in Sept. 20 comments on FDA's sodium labeling final rule. Although the Nonprescription Drug Manufacturers Association "agrees in principle it could be useful to [identify] the quantity of sodium in labeling of certain OTC drug products," the association "disagrees with the across-the-board sodium warning requirement for all orally-ingested OTC drugs."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning